Yale Department of Psychiatry Chairman to Join Clearmind


Dr. John H. Krystal, world expert on alcoholism and depression, will serve on the Scientific Advisory Board

VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“clear mind“or the”Company“), a biotechnology company focused on the discovery and development of novel psychedelic-derived therapies to address major undertreated health problems, today announced the appointment to its Scientific Advisory Board of John Krystal, Chairman of the Department of Psychiatry from Yale University School of Medicine.

A leading expert in alcoholism, post-traumatic stress disorder, schizophrenia and depression, Dr. Krystal’s work combines psychopharmacology, neuroimaging, molecular genetics and computational neuroscience to study the neurobiology and treatment of these troubles. He is best known for leading the discovery of the rapid antidepressant effects of ketamine.

“We are truly honored to add Dr. Krystal, one of the world’s most recognized experts on alcoholism, to our Scientific Advisory Board,” said Dr. Adi Zuloff-Shani, CEO of Clearmind. “Clearmind has focused on collaborating with scientists and clinicians at the world’s top academic, medical and research institutions, helping us bring innovative expertise to meet some of the world’s most pressing health needs.

Dr. Krystal is a professor of translational research; Psychiatry, Neurosciences and Psychology; he chairs the Department of Psychiatry at Yale University; and he is chief of psychiatry and behavioral health at Yale-New Haven Hospital. He graduated from the University of Chicago and Yale University School of Medicine.

Among many other positions he holds or has held, Dr. Krystal is Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD, Co-Director of the Neuroscience Forum of the US National Academies of science, engineering and medicine; and editor of Biological Psychiatry (IF = 12.1). He is a Fellow of the US National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.

“We believe that the scientists on our Scientific Advisory Board, working closely with us to challenge, validate and guide our scientific program of developing breakthrough therapies that improve human mental health at scale, increase access to care , reduce suffering and improve health outcomes around the world,” Zuloff-Shani said.

About Clearmind Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0)

Clearmind is a new biotechnology company focused on the discovery and development of safe and innovative therapies derived from psychedelics to treat alcohol use disorders and other pressing health issues.

The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindan, a new psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic in acquiring additional intellectual property to build its portfolio.

Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D capabilities and discover new candidate treatments for other mental health conditions.

For more information, please contact:

Investor Relations

[email protected]

Phone: (604) 260-1566

General Information

[email protected]



This press release may contain forward-looking statements and information based on current expectations. These statements should not be construed as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those implied by such statements. These representations include the timely submission of relevant documentation to the satisfaction of the relevant regulatory authorities and the raising of sufficient funding to carry out the Company’s business strategy. There is no certainty that any of these events will occur. Although these statements are based on management’s reasonable assumptions, there can be no assurance that these assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing in early-stage companies inherently involves a high degree of risk, and an investment in securities of the Company should be considered highly speculative.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of the securities in any province where such offer, solicitation or sale would be unlawful. The securities issued or to be issued pursuant to the Private Placement have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States in the United States. lack of registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. .


About Author

Comments are closed.